Synthesis and anticonvulsant evaluation of a series of (R)- and (S)-N-Cbz-α-aminoglutarimide and succinimide

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 12, 1996, Pages 1297-1302

  Park, Minsoo ^a   Lee, Jaewon ^b   Choi, Jongwon ^a  

^a Kyungsung University   (South Korea)

^b Koshin Medical Center Pusan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ETHOSUXIMIDE; GLUTARIMIDE DERIVATIVE; MESUXIMIDE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; SUCCINIMIDE DERIVATIVE; TRIMETHADIONE; VALPROIC ACID;

ABSENCE; ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CONVULSION; DRUG SCREENING; DRUG SYNTHESIS; ELECTRIC SHOCK; ENANTIOMER; EPILEPSY; LIVER TOXICITY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; TONIC CLONIC SEIZURE;

ANIMALIA;

EID: 0029937564     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00220-X     Document Type: Article

References (31)

1. (a) Liebmann, J. M.; Schneider, J. A. Annu. Rep. Med. Chem. 1985, 20, 11.
2. (b) Swinyard, E. A. Antiepilepic Drug; 2nd Ed.; Ravan Press: New York, 1982; p. 5.
3. Schmidt, D. Epilepsia, 1984, 25, 244.
4. (a) Lindhart, D; Hopperner, R. J. E. A. Epilepsia, 1984, 25, 77.
5. Vida, J. A. Principle of Medicinal Chemistry, Foye, W. O., Ed; Lea & Febiger: Philadelphia, 1995, Chap. 11.
6. (a) Kohn, H.; Sawhney, K. N.; LeGall, D.; Leader, J. D. J. Med. Chem. 1991, 34, 2444.
7. (b) Kohn, H.; Sawhney, K. N.; LeGall, D.; Cinley, J. D. J. Med. Chem. 1990, 33, 919.
8. (c) Conley, J. D.; Kohn, H. J. Med. Chem., 1987, 30, 567.
9. (a) Takahashi, J.; Ogui, K.; Fujimura, H.; Satoda, I.; Fukui, T.; Yamamoto, Y. Swiss Patent 393355, Oct. 30, 1965.
10. (b) Thorne, D. E. U.S. Patent. 3657341, April 8, 1972.
11. (a) Brouillette, W. J.; Jestkov, V. P.; Brown, M. L.; Akhatar, M. S.; DeLorey, T. M.; Brown, G. B. J. Med. Chem. 1994, 37, 3289.
12. (b) Kwon, C. H.; Iqbal, M. T.; Eurpel, J. N. D. J. Med. Chem. 1991, 34, 1845.
13. (c) Sergio C.; Liao, Z. K.; Watson, D.; Kohn, H. J. Med. Chem. 1985, 28 601
14. (d) Moustafa, M. M. M.; Dumont, P. J. Med. Chem. 1984, 27, 76.
15. (e) Woodbury, D. M. Drug Dev. Res. 1982, 2, 333.
16. (a) Farrar, V. A.; Ciechanowicz-Rutkowska, M.; Grochowski, J.; Serda, P.; Pilati, J.; Filippini, G.; Hinko, C. N.; El-Assadi, A; Moore, J. A.; Edafiogho, I. O.; Andrew, C. W.; Cory, M.; Nicholson, J. M.; Scott, K. R. J. Med. Chem. 1993, 36, 3517.
17. (b) Edafiogho, I. O.; Scitt, K. R.; Moore, J. A.; Farrar, V.A.; Nicholson, J. M. J. Med. Chem. 1991, 34, 387.
18. (c) Borenstein, M.R.; Duukas, P. H. J. Pharm. Sci. 1987, 76, 300.
19. (d) Kornet, M. J. J. Pharm. Sci. 1984, 73, 405.
20. (a) Witiak, D. T.; Seth, S. K.; Baizmann, E. R.; Weibel, S. L.; Wolf, H. H. J. Med. Chem. 1976, 19, 1419.
21. (b) Aboul-Eneine, H. Y.; Schauberger, C. W.; Hansen, A. R.; Fischer, L. J. J. Med. Chem. 1975, 18, 736.
22. (a) Andersen, K. E.; Braestrup, C; Gronwald, F. C.; Jorgensen, A. S.; Nielsen, E. B.; Sonnewald, U.; Sorensen, P. O.; Suzdak, P. D.; Knutsen, L. J. S. J. Med. Chem. 1993, 36, 1716.
23. (b) N'Goka, V.; Schlewer, G.; Linget, J. M.; Chambon, J. P.; Wermuth, C. G. J. Med. Chem. 1991, 34, 2547.
24. (c) Brake, J. R.; Silvermann, R.B. J. Am. Chem. Soc. 1991, 113, 9329.
25. (a) Pook, P. C. K.; Jane, D. E.; Watkins, J. C. J. Med. Chem. 1994, 37, 4288.
26. (b) Heckendorn, R.; Allgeier, H.; Baud, J.; Grunzenhauser, W.; Angst, C. J Med. Chem. 1993, 36, 3721.
27. For the preparation of 4: Itoh, M. Chem. Pharm. Bull. 1969, 17, 1679. ; For the preparation of 1 and 2: Sandler, S. R.; Karo, W. Organic Functional Group Preparation; Academic Press: New York, 1972, Vol III, p. 253.
28. For the preparation of 4: Itoh, M. Chem. Pharm. Bull. 1969, 17, 1679. ; For the preparation of 1 and 2: Sandler, S. R.; Karo, W. Organic Functional Group Preparation; Academic Press: New York, 1972, Vol III, p. 253.
29. (a) Swinyard. E.A.; Woodhead, J. H.; White, H. S.; Franklin, M. R. General Priciples, Experimental Section, Quantification and Evaluation of Anticonvulsants in Antiepileptic Drugs, 3rd Ed, Levy, R. Ed. New York, Ravan Press, 1988, p. 88.
30. (b) Krall, R. L.; Penry, J. K.; White, B. G.; Kupferberg, H. J; Swinyard, C. A. Epilepsia, 1978, 19, 409. The pharmacological tests were carried out as follows: All the tested compounds were dissolved in polyethylene glycol 400 and administered ip to male ICR mice and anticonvulsant tests were performed in groups of 4 mice and 30 min after administration. Seizure were then artificially induced by either electric shock or pentylenetetrazole. The maximal elelectric shock seizure(MES) test were elicited with a 60-cycle a.c. of 50 mA intensity delivered for 0.2 s via corneal electrod with ECT unit(UGO Basline, Itlay). A drop of 0.9% saline was istilled in the eye prior to application of electrods. Protection in this test was defined as the abolition of hind limb tonic extension component of seizure. The pentylenetetrazole seizure (PTZ) test entailed the administration of 80 mg/kg of pentylenetetrazole as a 0.5 % solution subcutaneously in the posterior midline of mice. And the animal was observed for 30 min. Protection was defined as the failure to observe even a threshold seizure(single episode of clonic spasms of at least 5 sec. duration). The effects of the compounds on forced and spontaneous motor activity were evaluated in mice by the rotorod test with Rotorod treadmill for mice(UGO Baseline, Itlay) as follows. The animal was placed on a rod an 1 inch diameter knurled plastic rod rotating at 6 rpm after the administration of the compounds. Normal mice can remain on a rod at this speed indifinitely. Neurological toxicity was defined as the failure of the animal to remain on the rod for 2 min.
31. Porter, R. J.; Cereghino, J. J.; Gladding, G. D.; Hessie, B. J.; Kupferberg, H. J.; Scoville, B.; White, B. G. Cleveland Clin. Q. 1984, 51, 283.